Ventricular Remodeling

The grounding supports myocardial infarction as the main cause of ventricular remodeling. The literature also links the post-infarction inflammatory response, ischemia-reperfusion injury, and broader pathological cardiac injury to the remodeling process.

After myocardial infarction, necrosis triggers complement activation, free radical generation, and a cytokine cascade, including TNF-alpha release, with IL-8 and C5a contributing to neutrophil recruitment in ischemic and reperfused myocardium. The remodeling process is associated with structural, cellular, and molecular changes that affect ventricular function, stroke volume, signaling pathways, inflammation, fibrosis, cell death, hypertrophy, oxidative stress, mitochondrial dysfunction, and energy metabolism.

The supplied literature identifies diabetes, chronic obstructive pulmonary disease, and female sex as factors that shape progression of post-myocardial infarction remodeling. More generally, the condition follows myocardial infarction and is influenced by the severity of the inflammatory and reparative response.

Management is described at the level of heart-failure and remodeling-directed drug classes rather than specific regimens. The grounding supports use of heart-failure drugs that act on general pathways involved in remodeling, and it specifically notes sodium-glucose cotransporter 2 inhibitors as guideline drugs in heart-failure management; targeted drugs for remodeling are described as absent.